Panel says NSAID labels should not change

Share this article:

An FDA advisory panel said naproxen should not get a heart-friendly label that would indicate it may have a cardiovascular edge over other drugs in its drug class. Medpage Today reports the advisory panel voted 16-9 against a new label, saying there was insufficient evidence to support a change.

The "no" vote does not mean panelists do not think drugs like Aleve may have an edge over other medications. “If I were forced to bet on what the truth is, my bet would be that naproxen is safer,” Susan Ellenberg told the Associated Press.

The panel's decision followed two days of discussions which were prompted by more than 700 studies finding fewer heart problems with OTC and prescribed naproxen compared to other NSAIDs.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.